TOP STORIES

Sarepta CEO Ingram Exits Amid Elevidys Sales Pressure—Succession During Competitive Inflection

Sarepta Therapeutics CEO Doug Ingram announced February 25 that he will retire by year-end or when a replacement is found, as the company confronts declining sales of its gene therapy Elevidys and intensifying competition in Duchenne muscular dystrophy. On an earnings call, Ingram revealed that his wife and son were recently diagnosed with myotonic dystrophy type 1 (DM1), a disease Sarepta began pursuing in 2024 through a partnership with Arrowhead Pharmaceuticals. As FiercePharma reported, Elevidys Q4 sales fell to $110 million, down 16% sequentially, following an FDA label restriction in November that limited the gene therapy to ambulatory patients aged 4 and older after two non-ambulatory patient deaths from acute liver failure. Sarepta guided 2026 revenue at $1.2–1.4 billion, per STAT News. Shares fell 82% in 2025 (Reuters).

Competitive implications: PTC Therapeutics, with its own exon-skipping DMD franchise, and Solid Biosciences, advancing a competing gene therapy, stand to benefit if Sarepta’s leadership vacuum creates execution uncertainty. William Blair analyst Sami Corwin noted that investors hold “polarizing views” of Ingram and that succession uncertainty could cause further share price volatility. Leerink Partners analyst Joseph Schwartz said the departure was unsurprising “given the tumultuous last year.” Dyne Therapeutics and Entrada Therapeutics, both pursuing DM1 programs, may find partnership and BD discussions easier if Sarepta’s strategic direction remains unclear. The succession also affects broader rare disease M&A: Sarepta has been both acquirer and potential target, and a prolonged CEO search could stall either scenario.

Key risks: An extended search or internal candidate misstep could accelerate Elevidys market share loss to future competitors. If the board prioritizes DM1 expertise over DMD commercial execution, the core franchise may suffer.

Solicitor General Targets Skinny Label Ruling—Generic Pathway at Supreme Court Crossroads

U.S. Solicitor General John Sauer filed a brief this week urging the Supreme Court to overturn the Federal Circuit’s decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), which revived Amarin’s induced infringement lawsuit over a skinny-labeled generic of Vascepa. The Court granted certiorari on January 16. Sauer argued that the Federal Circuit ruling threatens the Hatch-Waxman framework’s Section viii carve-out mechanism by exposing generic manufacturers to infringement claims based on commonplace statements such as calling their product a “generic version” of the branded drug. Consumer advocacy group Public Citizen filed a separate brief supporting Hikma the same week. The case turns on whether Hikma’s press releases, website, and marketing—which did not mention Vascepa’s patented cardiovascular indication—can plausibly support induced infringement of Amarin’s method-of-use patents.

Competitive implications: All generic manufacturers relying on Section viii skinny labels face heightened litigation risk if the Federal Circuit precedent stands. Amarin‘s Vascepa franchise—which generated $654 million in the first nine months of 2025, per BioPharma Dive—is directly at stake, with the cardiovascular indication driving the majority of revenue. Companies with strong method-of-use patent estates, particularly in cardiovascular, oncology, and neurology, would see immediate valuation upside from narrower generic pathways. Teva, Viatris, and other diversified generics players have the most to lose if the Court sides with branded manufacturers. Duane Morris noted that a decision tightening inducement standards could reinforce the carve-out pathway and support earlier generic entry.

Key risks: Oral argument has not yet been scheduled; a ruling is not expected before June at the earliest. A ruling favoring brand manufacturers could trigger a wave of retroactive infringement suits against already-launched skinny-label generics. Generic manufacturers may preemptively delay launches or abandon certain markets entirely if liability exposure becomes untenable.

Generate Prices $400M IPO—Largest Biotech Offering Signals Capital Market Reopening

Generate Biomedicines priced its initial public offering at $16 per share, selling 25 million shares for $400 million in gross proceeds—the largest biotech IPO since 2024, per BioPharma Dive. The deal, which was oversubscribed according to Bloomberg, implies a market capitalization of approximately $2 billion. Shares began trading February 27 on Nasdaq under the ticker GENB. Generate is the fifth biotechnology company to go public in February, bringing the month’s cumulative biotech IPO proceeds to nearly $1.4 billion. The Somerville, Massachusetts-based company, founded in 2018 by Flagship Pioneering, had previously raised more than $800 million in venture capital and approximately $110 million from collaborations with Amgen and Novartis. Goldman Sachs and Morgan Stanley led the offering.

Competitive implications: Other AI drug discovery platforms seeking public market access face a higher bar, as Generate’s scale and capital raise set expectations for comparable offerings. Established computational biology firms including Schrödinger and Relay Therapeutics face renewed funding competition from well-capitalized entrants. Large pharma partnerships—already a key validation mechanism for AI platforms—become even more critical as public investors demand external validation. If Generate’s stock underperforms, the IPO window for platform biotechs could narrow quickly, forcing peers back to private markets or strategic sales.

Key risks: Generate must deliver clinical-stage assets within 18-24 months to maintain investor confidence. Continued share price weakness could trigger down rounds for other AI discovery companies or force them to accept lower valuations in strategic exits.

REGULATORY & APPROVALS

• The EMA’s CHMP recommended marketing authorization for Moderna‘s mCombriax (mRNA-1083), the world’s first flu-COVID combination vaccine, for adults 50 and older. The recommendation was based on a Phase 3 trial of 8,000 participants showing non-inferior immune responses versus co-administered Spikevax and standard flu vaccines (BioPharma Dive). Moderna withdrew its U.S. combination application in May 2025 after FDA demanded additional flu efficacy data and is awaiting guidance on refiling. Per CIDRAP, mCombriax could be available in certain EU markets for the 2026–2027 season.
• FDA granted Ascendis Pharma accelerated approval for YUVIWEL (navepegritide), a once-weekly C-type natriuretic peptide analog for children aged 2+ with achondroplasia, based on annualized growth velocity as a surrogate endpoint. Continued approval is contingent on confirmatory trials. YUVIWEL joins BioMarin‘s daily-injection Voxzogo as the second approved achondroplasia therapy; BridgeBio‘s oral infigratinib (Phase 3 positive Feb 12) plans NDA filing H2 2026. FDA also issued a Rare Pediatric Disease Priority Review Voucher.
• Boehringer Ingelheim secured first-line approval for Hernexeos in a rare NSCLC tumor subset less than six months post-launch using the FDA’s second Commissioner’s National Priority Voucher.
• FDA issued a warning letter to ExThera for promoting its Seraph 100 blood filter device to cancer patients outside authorized conditions, signaling heightened scrutiny of off-label marketing in blood purification technologies.

CLINICAL DATA

• Seagen and Merck’s Padcev-Keytruda combination achieved positive Phase 3 results in first-line bladder cancer, building on prior success and positioning the ADC-IO pairing as a potential standard-of-care anchor.
• Bristol Myers Squibb’s antibody-drug conjugate hit dual primary survival endpoints in a Chinese Phase 3 breast cancer trial, validating the company’s $8.4 billion ADC acquisition bet.
• Merck’s HIF-2α inhibitor Welireg delivered positive results in dual combination trials for clear cell renal cell carcinoma, though unspecified barriers to becoming standard of care remain.
• Novartis reported Phase 2 data showing all three doses of Rhapsido outperformed placebo in food allergy, setting up potential label expansion beyond chronic urticaria.

DEALS & PARTNERSHIPS

• Eli Lilly inaugurated LillyPod, a DGX SuperPOD with 1,016 Nvidia Blackwell Ultra GPUs delivering over 9,000 petaflops of AI performance—the most powerful supercomputer wholly owned by a pharmaceutical company, per HPCwire. The system, assembled in four months, will train protein diffusion models and genomics foundation models for drug discovery. This builds on a $1 billion five-year co-innovation lab announced at the J.P. Morgan Healthcare Conference in January.
• Atrium Therapeutics launched with $270 million and two preclinical cardiovascular programs from Novartis’ $12 billion Avidity Biosciences acquisition, completing a spinout announced last October.
• Quantum Surgical acquired NeuWave Medical from Johnson & Johnson, adding microwave ablation technology for cancer treatment to its interventional radiology portfolio.

BUSINESS & FINANCE

• Alkermes CEO Richard Pops will step down after leading the company since 1991. COO Blair Jackson, with Alkermes since 1999, was named successor effective August 1; Pops transitions to chairman and advisor. Per FierceBiotech, Jackson led the 2024 divestiture of Alkermes’ oncology business, the Athlone manufacturing sale, and the $2.4 billion Avadel Pharmaceuticals acquisition. The transition occurs while late-stage narcolepsy programs advance.
• Merck is ending Gardasil manufacturing at its Durham, NC vaccine plant and laying off 147 employees, citing worldwide reduction in demand for the HPV vaccine franchise.
• Charles River Laboratories divested its contract manufacturing operation and European discovery services, representing $287 million in 2025 revenue, fulfilling its November commitment to shed 7% of business.
• Viatris disclosed plans to reduce headcount by up to 10% globally as part of a restructuring targeting up to $700 million in annual savings.
• The US International Trade Commission launched an investigation examining whether China’s support for its biotech sector and pricing practices constitute market manipulation disadvantaging American biotechnology firms.

WHAT TO WATCH NEXT

Supreme Court Skinny Label Decision—Hikma v. Amarin Oral Arguments Pending

The Supreme Court will decide Hikma v. Amarin (No. 24-889), with cert granted January 16 but oral argument not yet scheduled. The case asks two questions: whether calling a product “generic Vascepa” and citing public sales data constitutes induced infringement when the label fully carves out the patented use, and whether a complaint can state an inducement claim without alleging any instruction that mentions the patented method (Duane Morris analysis). Watch for oral argument scheduling and amicus briefs from generic trade associations and consumer groups; a ruling is expected by June 2026 term end. A ruling favoring branded manufacturers would create new leverage to extend market exclusivity across dozens of pending skinny-label generic applications.

Moderna U.S. Combo Vaccine Refiling—FDA Regulatory Path Unclear

Moderna withdrew its U.S. application for mCombriax in May 2025 after FDA demanded additional flu efficacy data. The company has since accumulated that data and used it to seek approval of a standalone mRNA flu vaccine, but that application was initially refused to file by FDA over comparator vaccine concerns before the agency reversed course after Moderna amended the submission. Moderna said on its February investor call that it is awaiting FDA guidance on refiling the combination application. If FDA requires a new Phase 3 efficacy study rather than accepting the existing 8,000-participant immunogenicity trial used for EMA approval, U.S. commercialization could slip well past the 2026–2027 flu season, conceding market positioning to separate flu and COVID shots from competitors including Pfizer and Novavax.

Sarepta CEO Succession—Elevidys Franchise at Crossroads

Sarepta‘s board is searching for Ingram’s replacement among both internal and external candidates, per BioPharma Dive. Ingram will remain until year-end or until a successor is named. The transition occurs as FDA has approved Sarepta to study an immunosuppressive Elevidys regimen aimed at reversing the ambulatory-only label restriction (FiercePharma). The company ended 2025 with approximately $1 billion in cash and expects to be cash-flow positive in 2026. Watch for signals on whether the board prioritizes rare disease commercial expertise versus pipeline development experience—and whether BridgeBio, Solid Biosciences, or other competitors capitalize on Sarepta’s leadership uncertainty to accelerate their own DMD programs.